{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:48:05Z","timestamp":1778618885115,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000902","name":"Pediatric Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000902","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Paul Luisi Jr. Foundation"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.bbmt.2016.01.019","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T11:45:51Z","timestamp":1452944751000},"page":"698-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with\u00a0Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"22","author":[{"given":"Stacey","family":"Zahler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4629-2702","authenticated-orcid":false,"given":"Sumith","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmella","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Fabricatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Wolownik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Cooney-Qualter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee Ann","family":"Baxter-Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Luisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Militano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9862-510X","authenticated-orcid":false,"given":"Morris","family":"Kletzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.01.019_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2005-10-4004","article-title":"Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group","volume":"108","author":"Aplenc","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pbc.20646","article-title":"Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep","volume":"46","author":"Woods","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2016.01.019_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1634\/theoncologist.12-3-341","article-title":"Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia","volume":"12","author":"Meshinchi","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2016.01.019_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V97.1.56","article-title":"A\u00a0comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission","volume":"97","author":"Woods","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry","volume":"341","author":"Socie","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.01.019_bib6","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood-2002-01-0294","article-title":"Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival","volume":"100","author":"Wagner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib7","unstructured":"Pasquini MC WZ. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides,\u00a02013; https:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/pages\/index.aspx."},{"key":"10.1016\/j.bbmt.2016.01.019_bib8","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood-2010-01-261958","article-title":"Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors","volume":"116","author":"Shaw","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/pbc.21207","article-title":"Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age","volume":"49","author":"Perkins","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2016.01.019_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bbmt.2011.11.007","volume":"18","author":"Satwani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.019_bib11","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2010.32.5001","article-title":"Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?","volume":"29","author":"Horan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2012.12.005","article-title":"Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients","volume":"19","author":"Satwani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.019_bib13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/bmt.2010.209","article-title":"A\u00a0pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents","volume":"46","author":"Styczynski","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.019_bib14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2141.2011.08822.x","article-title":"A\u00a0comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients","volume":"155","author":"Geyer","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.21303","article-title":"Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases","volume":"50","author":"Satwani","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2016.01.019_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bmt.1705240","article-title":"Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML","volume":"37","author":"Horn","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.019_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12002","article-title":"The future role of monoclonal antibody therapy in childhood acute leukaemias","volume":"159","author":"Barth","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib18","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V86.8.3097.3097","article-title":"Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87","volume":"86","author":"Creutzig","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib19","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bbmt.2016.01.019_bib21","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib22","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2002-07-1947","article-title":"Gemtuzumab ozogamicin: first clinical experiences in children with relapsed\/refractory acute myeloid leukemia treated on compassionate-use basis","volume":"101","author":"Zwaan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib23","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2007.13.0096","article-title":"Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group","volume":"26","author":"Aplenc","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib24","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2009.08011.x","article-title":"Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study","volume":"148","author":"Zwaan","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V122.21.491.491","article-title":"Negative prognostic impact of high CD33 expression is negated with the use of gemtuzumab ozogamicin: a report from the Children's Oncology Group","volume":"122","author":"Pollard","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib27","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib28","article-title":"Gemtuzumab ozogamicin reduces relapse risk in FLT3\/ITD acute myeloid leukemia: a report from the Children's Oncology Group","author":"Tarlock","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2016.01.019_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1705785","article-title":"Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases","volume":"40","author":"Bradley","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.019_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bmt.1704399","article-title":"A\u00a0pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients","volume":"33","author":"Del Toro","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.019_bib31","doi-asserted-by":"crossref","first-page":"7164s","DOI":"10.1158\/1078-0432.CCR-1004-0018","article-title":"Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia","volume":"11","author":"Roman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2016.01.019_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbmt.2003.11.005","article-title":"A\u00a0pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients","volume":"10","author":"Osunkwo","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.019_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bbmt.2009.10.007","article-title":"An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients","volume":"16","author":"Bhatia","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.019_bib34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2016.01.019_bib35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pbc.21239","article-title":"Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation","volume":"50","author":"Roman","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2016.01.019_bib36","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/j.bbmt.2012.11.355","article-title":"Low dose liposomal amphotericin b followed by micafungin prophylaxis of invasive fungal infections (IFI) in pediatric allogeneic stem cell transplantation recipients","volume":"19","author":"Elmacken","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.019_bib37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/pbc.21043","article-title":"A\u00a0pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients","volume":"49","author":"Shereck","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2016.01.019_bib38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2141.2009.07770.x","article-title":"High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival","volume":"146","author":"Jacobsohn","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2016.01.019_bib40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjh.12528","article-title":"Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis","volume":"163","author":"Kharfan-Dabaja","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib41","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/blood-2013-10-535716","article-title":"Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens","volume":"123","author":"Bitan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib42","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2009-06-229369","article-title":"Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study","volume":"116","author":"Sun","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib43","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2010-08-303263","article-title":"Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients","volume":"117","author":"Smith","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/ejh.12508","article-title":"Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients","volume":"95","author":"Campregher","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib45","first-page":"Cd010189","article-title":"Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults","volume":"4","author":"Holtick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bbmt.2016.01.019_bib46","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1586\/era.11.37","article-title":"Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease","volume":"11","author":"Rizzari","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bbmt.2016.01.019_bib47","first-page":"557","article-title":"[Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia]","volume":"17","author":"Wan","year":"2009","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.bbmt.2016.01.019_bib48","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2010.153","article-title":"Clinical significance of flow cytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97\/MRC AML12 protocol","volume":"24","author":"van der Velden","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.01.019_bib49","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.019_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.03.5303","article-title":"High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia","volume":"24","author":"Lapillonne","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00432-014-1832-y","article-title":"Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases","volume":"141","author":"Woehlecke","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.019_bib53","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2009.51","article-title":"Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study","volume":"23","author":"Willasch","year":"2009","journal-title":"Leukemia"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116000598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116000598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:54:56Z","timestamp":1761058496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116000598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1083879116000598"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.01.019","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with\u00a0Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}